Critical Unmet Needs in DLBCL
Ian Flinn, MD, PhD, describes some of the important unmet needs of DLBCL, particularly in R/R DLBCL, and shares his hopes for the future of treatment.
EP: 1.Introduction: A 68-Year-Old Man with Diffuse Large B-Cell Lymphoma
EP: 2.Second-Line Treatment Approaches for R/R DLBCL
EP: 3.Available Treatment Options in DLBCL with 2 or More Relapses
EP: 4.An Oncologist’s Perspective on Future Treatment Options for the Profiled Patient and Targeted Treatment Approaches in R/R DLBCL
EP: 5.Critical Unmet Needs in DLBCL
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Challenges for Non–CAR T-Cell Treatment of Early Relapsed DLBCL
April 18th 2024During a Case-Based Roundtable® event, Elizabeth A. Brém, MD, discussed treatment approaches for a patient with early relapsed or primary refractory diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
Glofitamab Plus Chemo Improves Survival vs Rituximab in R/R DLBCL
April 16th 2024The phase 3 STARGLO trial met its primary end point, improving overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma with glofitamab and chemotherapy vs rituximab and chemotherapy.
Read More
